Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
A Phase II, Multicenter, Open-Label, Three-Cohort Trial Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
Status: Enrolling
Updated:  5/8/2012
Clinical Research Facility
mi
from
Phoenix, AZ
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
A Phase II, Multicenter, Open-Label, Three-Cohort Trial Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
Status: Enrolling
Updated: 5/8/2012
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
A Phase II, Multicenter, Open-Label, Three-Cohort Trial Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
Status: Enrolling
Updated:  5/8/2012
Clinical Research Facility
mi
from
Santa Clara, CA
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
A Phase II, Multicenter, Open-Label, Three-Cohort Trial Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
Status: Enrolling
Updated: 5/8/2012
Clinical Research Facility
mi
from
Santa Clara, CA
Click here to add this to my saved trials
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
A Phase II, Multicenter, Open-Label, Three-Cohort Trial Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
Status: Enrolling
Updated:  5/8/2012
Clinical Research Facility
mi
from
Daytona Beach, FL
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
A Phase II, Multicenter, Open-Label, Three-Cohort Trial Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
Status: Enrolling
Updated: 5/8/2012
Clinical Research Facility
mi
from
Daytona Beach, FL
Click here to add this to my saved trials
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
A Phase II, Multicenter, Open-Label, Three-Cohort Trial Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
Status: Enrolling
Updated:  5/8/2012
Clinical Research Facility
mi
from
Decatur, GA
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
A Phase II, Multicenter, Open-Label, Three-Cohort Trial Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
Status: Enrolling
Updated: 5/8/2012
Clinical Research Facility
mi
from
Decatur, GA
Click here to add this to my saved trials
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
A Phase II, Multicenter, Open-Label, Three-Cohort Trial Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
Status: Enrolling
Updated:  5/8/2012
Clinical Research Facility
mi
from
Park Ridge, IL
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
A Phase II, Multicenter, Open-Label, Three-Cohort Trial Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
Status: Enrolling
Updated: 5/8/2012
Clinical Research Facility
mi
from
Park Ridge, IL
Click here to add this to my saved trials
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
A Phase II, Multicenter, Open-Label, Three-Cohort Trial Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
Status: Enrolling
Updated:  5/8/2012
Clinical Research Facility
mi
from
Louisville, KY
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
A Phase II, Multicenter, Open-Label, Three-Cohort Trial Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
Status: Enrolling
Updated: 5/8/2012
Clinical Research Facility
mi
from
Louisville, KY
Click here to add this to my saved trials
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
A Phase II, Multicenter, Open-Label, Three-Cohort Trial Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
Status: Enrolling
Updated:  5/8/2012
Clinical Research Facility
mi
from
Philadelphia, PA
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
A Phase II, Multicenter, Open-Label, Three-Cohort Trial Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
Status: Enrolling
Updated: 5/8/2012
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
A Phase II, Multicenter, Open-Label, Three-Cohort Trial Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
Status: Enrolling
Updated:  5/8/2012
Clinical Research Facility
mi
from
Chattanooga, TN
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
A Phase II, Multicenter, Open-Label, Three-Cohort Trial Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
Status: Enrolling
Updated: 5/8/2012
Clinical Research Facility
mi
from
Chattanooga, TN
Click here to add this to my saved trials
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
A Phase II, Multicenter, Open-Label, Three-Cohort Trial Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
Status: Enrolling
Updated:  5/8/2012
Clinical Research Facility
mi
from
Dallas, TX
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
A Phase II, Multicenter, Open-Label, Three-Cohort Trial Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
Status: Enrolling
Updated: 5/8/2012
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
A Phase II, Multicenter, Open-Label, Three-Cohort Trial Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
Status: Enrolling
Updated:  5/8/2012
Clinical Research Facility
mi
from
Milwaukee, WI
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
A Phase II, Multicenter, Open-Label, Three-Cohort Trial Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
Status: Enrolling
Updated: 5/8/2012
Clinical Research Facility
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously to Patients With Advanced Solid Tumors
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously to Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  5/10/2012
Ramesh K. Ramanathan M.D.
mi
from
Scottsdale, AZ
Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously to Patients With Advanced Solid Tumors
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously to Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 5/10/2012
Ramesh K. Ramanathan M.D.
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously to Patients With Advanced Solid Tumors
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously to Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  5/10/2012
Mayo Clinic Scottsdale
mi
from
Scottsdale, AZ
Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously to Patients With Advanced Solid Tumors
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously to Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 5/10/2012
Mayo Clinic Scottsdale
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously to Patients With Advanced Solid Tumors
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously to Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  5/10/2012
cCare - California Cancer Associatesfor Research Excellence
mi
from
Encinitas, CA
Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously to Patients With Advanced Solid Tumors
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously to Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 5/10/2012
cCare - California Cancer Associatesfor Research Excellence
mi
from
Encinitas, CA
Click here to add this to my saved trials
Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously to Patients With Advanced Solid Tumors
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously to Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  5/10/2012
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously to Patients With Advanced Solid Tumors
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously to Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 5/10/2012
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously to Patients With Advanced Solid Tumors
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously to Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  5/10/2012
Jeffrey R. Infante
mi
from
Nashville, TN
Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously to Patients With Advanced Solid Tumors
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously to Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 5/10/2012
Jeffrey R. Infante
mi
from
Nashville, TN
Click here to add this to my saved trials
Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant
Pilot Study of Mechanical Stimulation for Prevention of Hematopoietic Cell Transplant Associated Bone Density Loss
Status: Archived
Updated:  5/11/2012
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant
Pilot Study of Mechanical Stimulation for Prevention of Hematopoietic Cell Transplant Associated Bone Density Loss
Status: Archived
Updated: 5/11/2012
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Phase 2b, Trial of Intravesical DTA-H19/PEI in Patients With Intermediate-Risk Superficial Bladder Cancer
Phase 2b, Multicenter Trial of Intravesical DTA-H19/PEI in Patients With Intermediate-Risk Superficial Bladder Cancer
Status: Enrolling
Updated:  5/13/2012
BCG Oncology
mi
from
Phoenix, AZ
Phase 2b, Trial of Intravesical DTA-H19/PEI in Patients With Intermediate-Risk Superficial Bladder Cancer
Phase 2b, Multicenter Trial of Intravesical DTA-H19/PEI in Patients With Intermediate-Risk Superficial Bladder Cancer
Status: Enrolling
Updated: 5/13/2012
BCG Oncology
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Lapatinib and Cetuximab in Patients With Solid Tumors
A Phase I Study of Lapatinib and Cetuximab in Patients With Solid Tumors
Status: Enrolling
Updated:  5/14/2012
Georgetown University Medical Center
mi
from
Washington,
Lapatinib and Cetuximab in Patients With Solid Tumors
A Phase I Study of Lapatinib and Cetuximab in Patients With Solid Tumors
Status: Enrolling
Updated: 5/14/2012
Georgetown University Medical Center
mi
from
Washington,
Click here to add this to my saved trials
Electromagnetic Tracking of Devices During Biopsy Procedures
Electromagnetic Tracking of Devices During Biopsy Procedures
Status: Enrolling
Updated:  5/14/2012
Mount Sinai Hospital
mi
from
New York, NY
Electromagnetic Tracking of Devices During Biopsy Procedures
Electromagnetic Tracking of Devices During Biopsy Procedures
Status: Enrolling
Updated: 5/14/2012
Mount Sinai Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Study of Gemcitabine, Oxaliplatin, and Paclitaxel in Patients With Refractory Germ Cell Carcinoma
A Phase II Study of Gemcitabine, Oxaliplatin, and Paclitaxel in Patients With Refractory Germ Cell Carcinoma
Status: Enrolling
Updated:  5/15/2012
Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Study of Gemcitabine, Oxaliplatin, and Paclitaxel in Patients With Refractory Germ Cell Carcinoma
A Phase II Study of Gemcitabine, Oxaliplatin, and Paclitaxel in Patients With Refractory Germ Cell Carcinoma
Status: Enrolling
Updated: 5/15/2012
Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Assessing the da Vinci® Robotic Surgical System for Surgery of the Upper Aerodigestive Tract
A Pilot Study Assessing Transoral Robotic Surgery (TORS) For Oral And Laryngopharyngeal Benign And Malignant Lesions Using The da Vinci® Robotic Surgical System
Status: Enrolling
Updated:  5/16/2012
Stanford University School of Medicine
mi
from
Stanford, CA
Assessing the da Vinci® Robotic Surgical System for Surgery of the Upper Aerodigestive Tract
A Pilot Study Assessing Transoral Robotic Surgery (TORS) For Oral And Laryngopharyngeal Benign And Malignant Lesions Using The da Vinci® Robotic Surgical System
Status: Enrolling
Updated: 5/16/2012
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Cyclosporine A in Combination With Nab-Paclitaxel in Patients With Metastatic Breast Cancer
A Phase I, Open-label, Study of the Safety and Tolerability of Cyclosporine A (CsA) in Combination With Nab-paclitaxel in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  5/17/2012
Northwestern University, Northwestern Medical Faculty Foundation
mi
from
Chicago, IL
Cyclosporine A in Combination With Nab-Paclitaxel in Patients With Metastatic Breast Cancer
A Phase I, Open-label, Study of the Safety and Tolerability of Cyclosporine A (CsA) in Combination With Nab-paclitaxel in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 5/17/2012
Northwestern University, Northwestern Medical Faculty Foundation
mi
from
Chicago, IL
Click here to add this to my saved trials
Dignity Therapy in mCRC to Increase Peaceful Awareness & Impact Goals of Care Decision-Making
Use of Dignity Therapy in Stage IV Colorectal Cancer Patients Receiving Chemotherapy to Increase Peaceful Awareness and Impact Goals of Care Decision-Making
Status: Enrolling
Updated:  5/17/2012
Northwestern University, Northwestern Memorial Faculty Foundation
mi
from
Chicago, IL
Dignity Therapy in mCRC to Increase Peaceful Awareness & Impact Goals of Care Decision-Making
Use of Dignity Therapy in Stage IV Colorectal Cancer Patients Receiving Chemotherapy to Increase Peaceful Awareness and Impact Goals of Care Decision-Making
Status: Enrolling
Updated: 5/17/2012
Northwestern University, Northwestern Memorial Faculty Foundation
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study of [F-18]HX4 (PET Imaging)Evaluated in Head and Neck Cancer Patients
A Phase I/II, Open Label, Nonrandomized, Multi-Center Study of [F-18]HX4 Positron Emission Tomography (PET) in Head and Neck Cancer Patients
Status: Enrolling
Updated:  5/17/2012
University of Iowa Medical Center
mi
from
Iowa City, IA
A Study of [F-18]HX4 (PET Imaging)Evaluated in Head and Neck Cancer Patients
A Phase I/II, Open Label, Nonrandomized, Multi-Center Study of [F-18]HX4 Positron Emission Tomography (PET) in Head and Neck Cancer Patients
Status: Enrolling
Updated: 5/17/2012
University of Iowa Medical Center
mi
from
Iowa City, IA
Click here to add this to my saved trials
Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
Post-Prostatectomy Erectile Dysfunction: Effect of Hyperbaric Oxygen Therapy
Status: Enrolling
Updated:  5/18/2012
The Hartford Hospital
mi
from
Hartford, CT
Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
Post-Prostatectomy Erectile Dysfunction: Effect of Hyperbaric Oxygen Therapy
Status: Enrolling
Updated: 5/18/2012
The Hartford Hospital
mi
from
Hartford, CT
Click here to add this to my saved trials
Dose Escalation Study to Assess the Safety and Tolerability of Genz-644282 in Patients With Solid Tumors
A Phase I, Open-Label, Multicenter, Dose Escalation Study to Assess the Safety and Tolerability of Genz-644282 in Patients With Advanced Malignant Solid Tumors
Status: Enrolling
Updated:  5/18/2012
TGen Clinical Research Services at Scottsdale Healthcare
mi
from
Scottsdale, AZ
Dose Escalation Study to Assess the Safety and Tolerability of Genz-644282 in Patients With Solid Tumors
A Phase I, Open-Label, Multicenter, Dose Escalation Study to Assess the Safety and Tolerability of Genz-644282 in Patients With Advanced Malignant Solid Tumors
Status: Enrolling
Updated: 5/18/2012
TGen Clinical Research Services at Scottsdale Healthcare
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Dose Escalation Study to Assess the Safety and Tolerability of Genz-644282 in Patients With Solid Tumors
A Phase I, Open-Label, Multicenter, Dose Escalation Study to Assess the Safety and Tolerability of Genz-644282 in Patients With Advanced Malignant Solid Tumors
Status: Enrolling
Updated:  5/18/2012
Moffitt Cancer Center
mi
from
Tampa, FL
Dose Escalation Study to Assess the Safety and Tolerability of Genz-644282 in Patients With Solid Tumors
A Phase I, Open-Label, Multicenter, Dose Escalation Study to Assess the Safety and Tolerability of Genz-644282 in Patients With Advanced Malignant Solid Tumors
Status: Enrolling
Updated: 5/18/2012
Moffitt Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
Dose Escalation Study to Assess the Safety and Tolerability of Genz-644282 in Patients With Solid Tumors
A Phase I, Open-Label, Multicenter, Dose Escalation Study to Assess the Safety and Tolerability of Genz-644282 in Patients With Advanced Malignant Solid Tumors
Status: Enrolling
Updated:  5/18/2012
Wayne State University, Division of Hematology/Oncology, Karmanos Cancer Institute
mi
from
Detroit, MI
Dose Escalation Study to Assess the Safety and Tolerability of Genz-644282 in Patients With Solid Tumors
A Phase I, Open-Label, Multicenter, Dose Escalation Study to Assess the Safety and Tolerability of Genz-644282 in Patients With Advanced Malignant Solid Tumors
Status: Enrolling
Updated: 5/18/2012
Wayne State University, Division of Hematology/Oncology, Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Dose Escalation Study to Assess the Safety and Tolerability of Genz-644282 in Patients With Solid Tumors
A Phase I, Open-Label, Multicenter, Dose Escalation Study to Assess the Safety and Tolerability of Genz-644282 in Patients With Advanced Malignant Solid Tumors
Status: Enrolling
Updated:  5/18/2012
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School
mi
from
New Brunswick, NJ
Dose Escalation Study to Assess the Safety and Tolerability of Genz-644282 in Patients With Solid Tumors
A Phase I, Open-Label, Multicenter, Dose Escalation Study to Assess the Safety and Tolerability of Genz-644282 in Patients With Advanced Malignant Solid Tumors
Status: Enrolling
Updated: 5/18/2012
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Fondaparinux (Arixtra) With Chemotherapy for Advanced Non-Small Cell Lung Cancer
Phase I Feasibility Study of the Combination of Fondaparinux (Arixtra) With Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  5/23/2012
University of Alabama at Birmingham
mi
from
Birmingham, AL
Fondaparinux (Arixtra) With Chemotherapy for Advanced Non-Small Cell Lung Cancer
Phase I Feasibility Study of the Combination of Fondaparinux (Arixtra) With Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 5/23/2012
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
The CEASE Study: Computer Based Educational Module for the Reduction of Arthralgia Syndrome Associated With Endocrine Therapy for Breast Cancer
Computer Based Educational Module for the Reduction of Arthralgia Syndrome Associated With Endocrine Therapy for Breast Cancer
Status: Enrolling
Updated:  5/29/2012
Georgetown University Hospital
mi
from
Washington,
The CEASE Study: Computer Based Educational Module for the Reduction of Arthralgia Syndrome Associated With Endocrine Therapy for Breast Cancer
Computer Based Educational Module for the Reduction of Arthralgia Syndrome Associated With Endocrine Therapy for Breast Cancer
Status: Enrolling
Updated: 5/29/2012
Georgetown University Hospital
mi
from
Washington,
Click here to add this to my saved trials
Study of Imatinib, a Platelet-derived Growth Factor Receptor Inhibitor, and LBH589, a Histone Deacetylase Inhibitor, in the Treatment of Newly Diagnosed and Recurrent Chordoma
Multicenter Phase I Study of Imatinib, a Platelet-derived Growth Factor Receptor Inhibitor, and LBH589, a Histone Deacetylase Inhibitor, in the Treatment of Newly Diagnosed and Recurrent Chordoma
Status: Enrolling
Updated:  5/31/2012
Massachusetts General Hospital
mi
from
Boston, MA
Study of Imatinib, a Platelet-derived Growth Factor Receptor Inhibitor, and LBH589, a Histone Deacetylase Inhibitor, in the Treatment of Newly Diagnosed and Recurrent Chordoma
Multicenter Phase I Study of Imatinib, a Platelet-derived Growth Factor Receptor Inhibitor, and LBH589, a Histone Deacetylase Inhibitor, in the Treatment of Newly Diagnosed and Recurrent Chordoma
Status: Enrolling
Updated: 5/31/2012
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Study of Imatinib, a Platelet-derived Growth Factor Receptor Inhibitor, and LBH589, a Histone Deacetylase Inhibitor, in the Treatment of Newly Diagnosed and Recurrent Chordoma
Multicenter Phase I Study of Imatinib, a Platelet-derived Growth Factor Receptor Inhibitor, and LBH589, a Histone Deacetylase Inhibitor, in the Treatment of Newly Diagnosed and Recurrent Chordoma
Status: Enrolling
Updated:  5/31/2012
University of Michigan
mi
from
Ann Arbor, MI
Study of Imatinib, a Platelet-derived Growth Factor Receptor Inhibitor, and LBH589, a Histone Deacetylase Inhibitor, in the Treatment of Newly Diagnosed and Recurrent Chordoma
Multicenter Phase I Study of Imatinib, a Platelet-derived Growth Factor Receptor Inhibitor, and LBH589, a Histone Deacetylase Inhibitor, in the Treatment of Newly Diagnosed and Recurrent Chordoma
Status: Enrolling
Updated: 5/31/2012
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Study of Imatinib, a Platelet-derived Growth Factor Receptor Inhibitor, and LBH589, a Histone Deacetylase Inhibitor, in the Treatment of Newly Diagnosed and Recurrent Chordoma
Multicenter Phase I Study of Imatinib, a Platelet-derived Growth Factor Receptor Inhibitor, and LBH589, a Histone Deacetylase Inhibitor, in the Treatment of Newly Diagnosed and Recurrent Chordoma
Status: Enrolling
Updated:  5/31/2012
University of Virginia
mi
from
Charlottesville, VA
Study of Imatinib, a Platelet-derived Growth Factor Receptor Inhibitor, and LBH589, a Histone Deacetylase Inhibitor, in the Treatment of Newly Diagnosed and Recurrent Chordoma
Multicenter Phase I Study of Imatinib, a Platelet-derived Growth Factor Receptor Inhibitor, and LBH589, a Histone Deacetylase Inhibitor, in the Treatment of Newly Diagnosed and Recurrent Chordoma
Status: Enrolling
Updated: 5/31/2012
University of Virginia
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Tesetaxel Every 3 Weeks vs Weekly vs Capecitabine as 1st-line Therapy for Locally Advanced or Metastatic Breast Cancer
A Randomized, Phase II Study of Tesetaxel Once Every 3 Weeks Versus Tesetaxel Once Weekly for 3 Weeks Versus Capecitabine Twice Daily for 14 Days as First-line Therapy for Subjects With Locally Advanced or Metastatic Breast Cancer
Status: Enrolling
Updated:  5/31/2012
The West Clinic, PC
mi
from
Memphis, TN
Tesetaxel Every 3 Weeks vs Weekly vs Capecitabine as 1st-line Therapy for Locally Advanced or Metastatic Breast Cancer
A Randomized, Phase II Study of Tesetaxel Once Every 3 Weeks Versus Tesetaxel Once Weekly for 3 Weeks Versus Capecitabine Twice Daily for 14 Days as First-line Therapy for Subjects With Locally Advanced or Metastatic Breast Cancer
Status: Enrolling
Updated: 5/31/2012
The West Clinic, PC
mi
from
Memphis, TN
Click here to add this to my saved trials
A Clinical Trial Comparing Gemcitabine and Carboplatin With and Without P276-00 in Subjects With Metastatic Triple Negative Breast Cancer, With a Run-in of Escalating Dose of P276-00 Added to Gemcitabine and Carboplatin
An Open-Label Randomized Phase II Trial Comparing Gemcitabine and Carboplatin With and Without P276-00 in Subjects With Metastatic Triple Negative Breast Cancer, With a Phase I Run-in of Escalating Dose of P276-00 Added to Gemcitabine and Carboplatin
Status: Enrolling
Updated:  6/1/2012
Disney Cancer Center
mi
from
Burbank, CA
A Clinical Trial Comparing Gemcitabine and Carboplatin With and Without P276-00 in Subjects With Metastatic Triple Negative Breast Cancer, With a Run-in of Escalating Dose of P276-00 Added to Gemcitabine and Carboplatin
An Open-Label Randomized Phase II Trial Comparing Gemcitabine and Carboplatin With and Without P276-00 in Subjects With Metastatic Triple Negative Breast Cancer, With a Phase I Run-in of Escalating Dose of P276-00 Added to Gemcitabine and Carboplatin
Status: Enrolling
Updated: 6/1/2012
Disney Cancer Center
mi
from
Burbank, CA
Click here to add this to my saved trials
A Clinical Trial Comparing Gemcitabine and Carboplatin With and Without P276-00 in Subjects With Metastatic Triple Negative Breast Cancer, With a Run-in of Escalating Dose of P276-00 Added to Gemcitabine and Carboplatin
An Open-Label Randomized Phase II Trial Comparing Gemcitabine and Carboplatin With and Without P276-00 in Subjects With Metastatic Triple Negative Breast Cancer, With a Phase I Run-in of Escalating Dose of P276-00 Added to Gemcitabine and Carboplatin
Status: Enrolling
Updated:  6/1/2012
3855 Health Sciences Drive
mi
from
La Jolla, CA
A Clinical Trial Comparing Gemcitabine and Carboplatin With and Without P276-00 in Subjects With Metastatic Triple Negative Breast Cancer, With a Run-in of Escalating Dose of P276-00 Added to Gemcitabine and Carboplatin
An Open-Label Randomized Phase II Trial Comparing Gemcitabine and Carboplatin With and Without P276-00 in Subjects With Metastatic Triple Negative Breast Cancer, With a Phase I Run-in of Escalating Dose of P276-00 Added to Gemcitabine and Carboplatin
Status: Enrolling
Updated: 6/1/2012
3855 Health Sciences Drive
mi
from
La Jolla, CA
Click here to add this to my saved trials
A Clinical Trial Comparing Gemcitabine and Carboplatin With and Without P276-00 in Subjects With Metastatic Triple Negative Breast Cancer, With a Run-in of Escalating Dose of P276-00 Added to Gemcitabine and Carboplatin
An Open-Label Randomized Phase II Trial Comparing Gemcitabine and Carboplatin With and Without P276-00 in Subjects With Metastatic Triple Negative Breast Cancer, With a Phase I Run-in of Escalating Dose of P276-00 Added to Gemcitabine and Carboplatin
Status: Enrolling
Updated:  6/1/2012
UC Davis Cancer Center
mi
from
Sacramento, CA
A Clinical Trial Comparing Gemcitabine and Carboplatin With and Without P276-00 in Subjects With Metastatic Triple Negative Breast Cancer, With a Run-in of Escalating Dose of P276-00 Added to Gemcitabine and Carboplatin
An Open-Label Randomized Phase II Trial Comparing Gemcitabine and Carboplatin With and Without P276-00 in Subjects With Metastatic Triple Negative Breast Cancer, With a Phase I Run-in of Escalating Dose of P276-00 Added to Gemcitabine and Carboplatin
Status: Enrolling
Updated: 6/1/2012
UC Davis Cancer Center
mi
from
Sacramento, CA
Click here to add this to my saved trials
A Clinical Trial Comparing Gemcitabine and Carboplatin With and Without P276-00 in Subjects With Metastatic Triple Negative Breast Cancer, With a Run-in of Escalating Dose of P276-00 Added to Gemcitabine and Carboplatin
An Open-Label Randomized Phase II Trial Comparing Gemcitabine and Carboplatin With and Without P276-00 in Subjects With Metastatic Triple Negative Breast Cancer, With a Phase I Run-in of Escalating Dose of P276-00 Added to Gemcitabine and Carboplatin
Status: Enrolling
Updated:  6/1/2012
Washington University
mi
from
St. Louis, MO
A Clinical Trial Comparing Gemcitabine and Carboplatin With and Without P276-00 in Subjects With Metastatic Triple Negative Breast Cancer, With a Run-in of Escalating Dose of P276-00 Added to Gemcitabine and Carboplatin
An Open-Label Randomized Phase II Trial Comparing Gemcitabine and Carboplatin With and Without P276-00 in Subjects With Metastatic Triple Negative Breast Cancer, With a Phase I Run-in of Escalating Dose of P276-00 Added to Gemcitabine and Carboplatin
Status: Enrolling
Updated: 6/1/2012
Washington University
mi
from
St. Louis, MO
Click here to add this to my saved trials
An A/B Dose Escalation Study of AbGn-7 Alone and With FOLFOX7 Treatment in Patients With Advanced Solid Tumors
A Phase 1 A/B Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AbGn-7 Therapy Alone and in Combination With the FOLFOX7 Treatment Regimen in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  6/3/2012
Fox Chase Cancer Center
mi
from
Philadephia, PA
An A/B Dose Escalation Study of AbGn-7 Alone and With FOLFOX7 Treatment in Patients With Advanced Solid Tumors
A Phase 1 A/B Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AbGn-7 Therapy Alone and in Combination With the FOLFOX7 Treatment Regimen in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 6/3/2012
Fox Chase Cancer Center
mi
from
Philadephia, PA
Click here to add this to my saved trials
An A/B Dose Escalation Study of AbGn-7 Alone and With FOLFOX7 Treatment in Patients With Advanced Solid Tumors
A Phase 1 A/B Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AbGn-7 Therapy Alone and in Combination With the FOLFOX7 Treatment Regimen in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  6/3/2012
The University of Texas Health Science Center-CTRC
mi
from
San Antonio, TX
An A/B Dose Escalation Study of AbGn-7 Alone and With FOLFOX7 Treatment in Patients With Advanced Solid Tumors
A Phase 1 A/B Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AbGn-7 Therapy Alone and in Combination With the FOLFOX7 Treatment Regimen in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 6/3/2012
The University of Texas Health Science Center-CTRC
mi
from
San Antonio, TX
Click here to add this to my saved trials
Low Dose Chemotherapy With Aspirin in Patients With Breast Cancer After Neoadjuvant Chemotherapy
Low Dose Metronomic Cyclophosphamide and Methotrexate Chemotherapy in Combination With Aspirin in Patients With Stage II-III Breast Cancer Who Fail to Achieve a Pathologic Complete Response After Neoadjuvant Chemotherapy
Status: Enrolling
Updated:  6/4/2012
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Low Dose Chemotherapy With Aspirin in Patients With Breast Cancer After Neoadjuvant Chemotherapy
Low Dose Metronomic Cyclophosphamide and Methotrexate Chemotherapy in Combination With Aspirin in Patients With Stage II-III Breast Cancer Who Fail to Achieve a Pathologic Complete Response After Neoadjuvant Chemotherapy
Status: Enrolling
Updated: 6/4/2012
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
Low Dose Chemotherapy With Aspirin in Patients With Breast Cancer After Neoadjuvant Chemotherapy
Low Dose Metronomic Cyclophosphamide and Methotrexate Chemotherapy in Combination With Aspirin in Patients With Stage II-III Breast Cancer Who Fail to Achieve a Pathologic Complete Response After Neoadjuvant Chemotherapy
Status: Enrolling
Updated:  6/4/2012
Maimonides Cancer Center
mi
from
Brooklyn, NY
Low Dose Chemotherapy With Aspirin in Patients With Breast Cancer After Neoadjuvant Chemotherapy
Low Dose Metronomic Cyclophosphamide and Methotrexate Chemotherapy in Combination With Aspirin in Patients With Stage II-III Breast Cancer Who Fail to Achieve a Pathologic Complete Response After Neoadjuvant Chemotherapy
Status: Enrolling
Updated: 6/4/2012
Maimonides Cancer Center
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Low Dose Chemotherapy With Aspirin in Patients With Breast Cancer After Neoadjuvant Chemotherapy
Low Dose Metronomic Cyclophosphamide and Methotrexate Chemotherapy in Combination With Aspirin in Patients With Stage II-III Breast Cancer Who Fail to Achieve a Pathologic Complete Response After Neoadjuvant Chemotherapy
Status: Enrolling
Updated:  6/4/2012
University of Vermont
mi
from
Burlington, VT
Low Dose Chemotherapy With Aspirin in Patients With Breast Cancer After Neoadjuvant Chemotherapy
Low Dose Metronomic Cyclophosphamide and Methotrexate Chemotherapy in Combination With Aspirin in Patients With Stage II-III Breast Cancer Who Fail to Achieve a Pathologic Complete Response After Neoadjuvant Chemotherapy
Status: Enrolling
Updated: 6/4/2012
University of Vermont
mi
from
Burlington, VT
Click here to add this to my saved trials
Treatment for Joint Pains Due to Aromatase Inhibitor Therapy in Breast Cancer
Aromatase Inhibitor-Induced Arthralgia: A Proposed Management Algorithm
Status: Enrolling
Updated:  6/5/2012
Baylor Clinic
mi
from
Houston, TX
Treatment for Joint Pains Due to Aromatase Inhibitor Therapy in Breast Cancer
Aromatase Inhibitor-Induced Arthralgia: A Proposed Management Algorithm
Status: Enrolling
Updated: 6/5/2012
Baylor Clinic
mi
from
Houston, TX
Click here to add this to my saved trials
Treatment for Joint Pains Due to Aromatase Inhibitor Therapy in Breast Cancer
Aromatase Inhibitor-Induced Arthralgia: A Proposed Management Algorithm
Status: Enrolling
Updated:  6/5/2012
Ben Taub General Hospital
mi
from
Houston, TX
Treatment for Joint Pains Due to Aromatase Inhibitor Therapy in Breast Cancer
Aromatase Inhibitor-Induced Arthralgia: A Proposed Management Algorithm
Status: Enrolling
Updated: 6/5/2012
Ben Taub General Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
Evaluation of Cardiovascular Health Outcomes Among Survivors
Evaluation of Cardiovascular Health Outcomes Among Survivors
Status: Enrolling
Updated:  6/6/2012
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Evaluation of Cardiovascular Health Outcomes Among Survivors
Evaluation of Cardiovascular Health Outcomes Among Survivors
Status: Enrolling
Updated: 6/6/2012
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Click here to add this to my saved trials
Radioactive Iodide (131I) Treatment of 124I PET/CT Detected Breast Cancers
Radioactive Iodide (131I) Treatment of 124I PET/CT Detected Breast Cancers
Status: Enrolling
Updated:  6/6/2012
Stanford University School of Medicine
mi
from
Stanford, CA
Radioactive Iodide (131I) Treatment of 124I PET/CT Detected Breast Cancers
Radioactive Iodide (131I) Treatment of 124I PET/CT Detected Breast Cancers
Status: Enrolling
Updated: 6/6/2012
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Vitamin E Supplements in Treating Patients Undergoing Surgery for Colorectal Cancer
A Randomized Study to Investigate the Presence of Tocopherol Metabolites in the Colon
Status: Enrolling
Updated:  6/12/2012
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School
mi
from
New Brunswick, NJ
Vitamin E Supplements in Treating Patients Undergoing Surgery for Colorectal Cancer
A Randomized Study to Investigate the Presence of Tocopherol Metabolites in the Colon
Status: Enrolling
Updated: 6/12/2012
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Vorinostat and Lapatinib in Advanced Solid Tumors and Advanced Breast Cancer to Evaluate Response and Biomarkers
Pilot and Phase II- Vorinostat and Lapatinib in Patients With Advanced Solid Tumor Malignancies and Women With Recurrent Local-Regional or Metastatic Breast Cancer to Evaluate Response and Biomarkers of EMT and Breast Cancer Stem Cells
Status: Enrolling
Updated:  6/12/2012
University of Maryland Greenebaum Cancer Center
mi
from
Baltimore, MD
Vorinostat and Lapatinib in Advanced Solid Tumors and Advanced Breast Cancer to Evaluate Response and Biomarkers
Pilot and Phase II- Vorinostat and Lapatinib in Patients With Advanced Solid Tumor Malignancies and Women With Recurrent Local-Regional or Metastatic Breast Cancer to Evaluate Response and Biomarkers of EMT and Breast Cancer Stem Cells
Status: Enrolling
Updated: 6/12/2012
University of Maryland Greenebaum Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials